Logo image of TOUR

TUNIU CORP-SPON ADR (TOUR) Stock Fundamental Analysis

USA - NASDAQ:TOUR - US89977P1066 - ADR

0.9155 USD
-0.02 (-2.23%)
Last: 10/7/2025, 8:00:01 PM
0.9101 USD
-0.01 (-0.59%)
After Hours: 10/7/2025, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, TOUR scores 3 out of 10 in our fundamental rating. TOUR was compared to 135 industry peers in the Hotels, Restaurants & Leisure industry. The financial health of TOUR is average, but there are quite some concerns on its profitability. TOUR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

TOUR had positive earnings in the past year.
TOUR had negative earnings in 4 of the past 5 years.
In multiple years TOUR reported negative operating cash flow during the last 5 years.
TOUR Yearly Net Income VS EBIT VS OCF VS FCFTOUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

1.2 Ratios

TOUR has a Return On Assets of 1.64%. This is comparable to the rest of the industry: TOUR outperforms 43.70% of its industry peers.
TOUR has a Return On Equity (2.92%) which is in line with its industry peers.
TOUR has a worse Return On Invested Capital (2.29%) than 67.41% of its industry peers.
Industry RankSector Rank
ROA 1.64%
ROE 2.92%
ROIC 2.29%
ROA(3y)-3.76%
ROA(5y)-11.5%
ROE(3y)-6.63%
ROE(5y)-24.79%
ROIC(3y)N/A
ROIC(5y)N/A
TOUR Yearly ROA, ROE, ROICTOUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

TOUR has a Profit Margin (5.59%) which is in line with its industry peers.
TOUR has a worse Operating Margin (5.19%) than 62.96% of its industry peers.
TOUR's Gross Margin of 64.21% is fine compared to the rest of the industry. TOUR outperforms 77.78% of its industry peers.
TOUR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.19%
PM (TTM) 5.59%
GM 64.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.93%
GM growth 5Y8.01%
TOUR Yearly Profit, Operating, Gross MarginsTOUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TOUR is destroying value.
The number of shares outstanding for TOUR has been reduced compared to 1 year ago.
Compared to 5 years ago, TOUR has less shares outstanding
TOUR has a better debt/assets ratio than last year.
TOUR Yearly Shares OutstandingTOUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TOUR Yearly Total Debt VS Total AssetsTOUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

TOUR has an Altman-Z score of -4.80. This is a bad value and indicates that TOUR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.80, TOUR is not doing good in the industry: 94.07% of the companies in the same industry are doing better.
TOUR has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TOUR has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. TOUR outperforms 89.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.8
ROIC/WACC0.25
WACC8.97%
TOUR Yearly LT Debt VS Equity VS FCFTOUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

2.3 Liquidity

TOUR has a Current Ratio of 1.63. This is a normal value and indicates that TOUR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.63, TOUR is in the better half of the industry, outperforming 74.81% of the companies in the same industry.
TOUR has a Quick Ratio of 1.63. This is a normal value and indicates that TOUR is financially healthy and should not expect problems in meeting its short term obligations.
TOUR's Quick ratio of 1.63 is fine compared to the rest of the industry. TOUR outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.63
Quick Ratio 1.63
TOUR Yearly Current Assets VS Current LiabilitesTOUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 188.89% over the past year.
The Revenue has been growing slightly by 7.71% in the past year.
Measured over the past years, TOUR shows a very negative growth in Revenue. The Revenue has been decreasing by -25.77% on average per year.
EPS 1Y (TTM)188.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)7.71%
Revenue growth 3Y6.46%
Revenue growth 5Y-25.77%
Sales Q2Q%15.53%

3.2 Future

TOUR is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.57% yearly.
TOUR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.88% yearly.
EPS Next Y-84.34%
EPS Next 2Y-48.52%
EPS Next 3Y-29.57%
EPS Next 5YN/A
Revenue Next Year8.66%
Revenue Next 2Y9.42%
Revenue Next 3Y9.88%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TOUR Yearly Revenue VS EstimatesTOUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2B 4B 6B 8B 10B
TOUR Yearly EPS VS EstimatesTOUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2023 2024 2025 2026 2027 0 -5 -10 -15

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 30.52, which means the current valuation is very expensive for TOUR.
TOUR's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.76, TOUR is valued at the same level.
Based on the Price/Forward Earnings ratio of 29.05, the valuation of TOUR can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TOUR is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of TOUR to the average of the S&P500 Index (23.21), we can say TOUR is valued slightly more expensively.
Industry RankSector Rank
PE 30.52
Fwd PE 29.05
TOUR Price Earnings VS Forward Price EarningsTOUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

70.37% of the companies in the same industry are cheaper than TOUR, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.59
TOUR Per share dataTOUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A cheap valuation may be justified as TOUR's earnings are expected to decrease with -29.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.52%
EPS Next 3Y-29.57%

3

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.04%, TOUR has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 6.99, TOUR pays a better dividend. On top of this TOUR pays more dividend than 84.44% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, TOUR pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.04%

5.2 History

TOUR does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
TOUR Yearly Dividends per shareTOUR Yearly Dividends per shareYearly Dividends per share 2025 0 0 0 0 0

5.3 Sustainability

DPN/A
EPS Next 2Y-48.52%
EPS Next 3Y-29.57%
TOUR Yearly Income VS Free CF VS DividendTOUR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B

TUNIU CORP-SPON ADR

NASDAQ:TOUR (10/7/2025, 8:00:01 PM)

After market: 0.9101 -0.01 (-0.59%)

0.9155

-0.02 (-2.23%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)08-15 2025-08-15/bmo
Earnings (Next)12-03 2025-12-03
Inst Owners8.84%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap107.76M
Analysts85.71
Price Target1.73 (88.97%)
Short Float %0.45%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield 3.04%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date03-27 2025-03-27 (0.036)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)62.5%
EPS NY rev (3m)62.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.03%
Revenue NY rev (3m)-4.03%
Valuation
Industry RankSector Rank
PE 30.52
Fwd PE 29.05
P/S 1.42
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.75
EV/EBITDA 20.59
EPS(TTM)0.03
EY3.28%
EPS(NY)0.03
Fwd EY3.44%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.65
BVpS1.24
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.64%
ROE 2.92%
ROCE 2.89%
ROIC 2.29%
ROICexc 2.29%
ROICexgc 2.34%
OM 5.19%
PM (TTM) 5.59%
GM 64.21%
FCFM N/A
ROA(3y)-3.76%
ROA(5y)-11.5%
ROE(3y)-6.63%
ROE(5y)-24.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.93%
GM growth 5Y8.01%
F-ScoreN/A
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.63
Quick Ratio 1.63
Altman-Z -4.8
F-ScoreN/A
WACC8.97%
ROIC/WACC0.25
Cap/Depr(3y)62.83%
Cap/Depr(5y)47.38%
Cap/Sales(3y)2.7%
Cap/Sales(5y)3.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)188.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-84.34%
EPS Next 2Y-48.52%
EPS Next 3Y-29.57%
EPS Next 5YN/A
Revenue 1Y (TTM)7.71%
Revenue growth 3Y6.46%
Revenue growth 5Y-25.77%
Sales Q2Q%15.53%
Revenue Next Year8.66%
Revenue Next 2Y9.42%
Revenue Next 3Y9.88%
Revenue Next 5YN/A
EBIT growth 1Y-59.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year611.95%
EBIT Next 3Y118.1%
EBIT Next 5YN/A
FCF growth 1Y-62.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.8%
OCF growth 3YN/A
OCF growth 5YN/A